Alnylam’s strategy to head off CRISPR threat

The disruptive potential CRISPR demonstrated last weekend led Alnylam to shed over $1 billion in market cap Monday, but the RNAi pioneer has been readying for this moment, building a pipeline strategy to counter the prospect it will end up playing second fiddle to the newer technology.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been anticipating the threat, CEO John Maraganore told BioCentury. It believes its long-term pipeline and commercialization game plan will enable it to maintain relevance when in vivo CRISPR meets the market. ...